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doi:10.101Early CMV Viremia Is Associated with Impaired Viral
Control following Nonmyeloablative Hematopoietic
Cell Transplantation with a Total Lymphoid Irradiation
and Antithymocyte Globulin Preparative Regimen
Joanna M. Schaenman,1 Sumana Shashidhar,2 Chanu Rhee,3 Jonathan Wong,1
Shelly Navato,2 RubyM.Wong,4 Dora Y. Ho,1 Sally Arai,2 Laura Johnston,2 Janice M. Brown1,2The reconstitution of immune function after hematopoietic cell transplant (HCT) plays an important role in
the control of viral infections. Both donor and recipient cytomegalovirus (CMV) serostatus has been shown
to contribute to effective immune function; however, the influence of a nonmyeloablative preparative (NMA)
regimen using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) on antiviral immune recon-
stitution has not yet been described. In 117 recipients of NMA HCT patients following ATG and TLI, not
unexpectedly, CMV viremia was seen in approximately 60% of the seropositive patients regardless of donor
serostatus, and recipient seropositivity significantly increased the odds of CMV viremia after transplant in
a multivariate analysis. The administration of ATG and TLI resulted in a strikingly earlier viremia in the post-
transplant period when compared to the previously reported timing of viremia following myeloablative pre-
parative regimens, especially for transplant recipients who were seropositive for CMV with seronegative
donors. Furthermore, early viremia in the setting of a CMV naı¨ve donor was associated with a delay in func-
tional antiviral control. These observations demonstrate the dynamic nature of immunity in relation to CMV
antigen exposure in the complex environment resulting from NMA conditions where both donor and resid-
ual recipient immune response affect viral control.
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Antithymocyte globulinINTRODUCTION
The study of posttransplant infection and disease
caused by common viral pathogens such as cytomegalo-
virus (CMV) offers a unique window into the develop-
ment of functional immunity after hematopoietic cell
transplantation (HCT). The development of CMV-
specific immunity is known tobe influencedbyanumber
of factors including the genetic relatedness of the
transplant donor to the patient, immunomodulatory
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6/j.bbmt.2010.08.010disease (GVHD) and its treatment, as well as the
serologic status of the transplant donor and recipient
[1,2]. The relative influence of each of these factors
has been delineated for patients undergoing trans-
plant following myeloablative (MA) conditioning
regimens [3,4]. However, the factors influencing the
reconstitution of effective antiviral response follow-
ing nonmyeloablative (NMA) preparative regimens,
especially those involving modulation of recipient
immunity, have not been well defined.
A preparative regimen utilizing total lymphoid
irradiation (TLI) and antithymocyte globulin (ATG)
has been shown to result in a decreased incidence of
acute GVHD (aGVHD) as well as a decrease in
transplant-associated toxicity [5,6]. We have observed
that viremia occurred earlier in CMV seropositive
patients, regardless of their donor serostatus,
compared to seronegative patients with seropositive
donors. In addition, there was a trend toward earlier
viremia in CMV seropositive patients with CMV
naive donors compared with patients with CMV
seropositive donors, and this early viremia was
associated with a delay in sustained viral control. Our693
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functional antiviral immunity following a TLI-ATG
preparative regimen suggest that, in addition to the
recognized influence of the donor experience with
CMV, the timing of viral exposure appears to have
a significant impact on the nascent immune system.METHODS
Transplant Protocol
A total of 177 patients who underwent a Stanford
program for NMA allogeneic HCT following a TLI
and ATG-based preparative regimen between Decem-
ber2001andDecember2007 in4 similar transplant pro-
tocols were reviewed for CMV seropositivity of donor
and recipient. Of these, 126 patients had either donor
or recipient seropositivity and 51 were negative for
both donor and recipient; 9 patients were not evaluated
because of insufficient data or participation in a CMV
prophylaxis trial resulting in 117 patients for further
analysis.Patientswereeligible for transplantunder these
4 protocols if they (1) had a diagnosis of malignant
lymphoid or myeloid disease including Hodgkin and
non-Hodgkin lymphoma, and (2) were not eligible for
conventional MA conditioning regimen because of age
.55 years, significant medical comorbidities, or exten-
sive exposure to prior chemotherapy regimens. Patients’
disease status at transplant ranged from complete remis-
sion to relapse as evaluatedbyconsensus guidelines.The
transplant protocol has been previously described [5,6]
and included TLI at 0.8 Gy per day administered daily
on days 11 through 7 and again from day 4 through
day 1 prior to the day of cell infusion as well as ATG
(thymoglobulin; Genzyme, Boston, MA) administered
intravenously at 1.5 mg/kg/day on days 11 through 7
prior to cell transplant. Donor cells were not T cell
depleted or otherwise manipulated prior to infusion.
Immunosuppressive regimens included cyclosporine
and mycophenolate mofetil. Antimicrobial prophylaxis
included fluconazole 400 mg by mouth once daily
through day 100 for most patients, acyclovir 400 mg
by mouth twice daily through day 100 for herpes
simplex virus (HSV) and/or varicella zoster virus
(VZV) seropositive patients, and ciprofloxacin 500 mg
by mouth twice daily during periods when absolute
neutrophil count was\500 cells/microliter.Posttransplant Monitoring
Chimerism, the percentage of donor DNA in bone
marrow or peripheral blood leukocytes, was determined
for all patients at days 28, 56, and 90 posttransplant us-
ing sequence-length polymorphic markers encoding
short tandem repeats [5]. Flow cytometry was used to
analyze the absolute number of CD31, CD41, CD81,
CD191, and NK cells at the same time points.If the patient, donor, or both were seropositive for
CMV, quantitative polymerase chain reaction (PCR)
testing of serumwas performed on a weekly basis using
the Amplicor CMV test (Roche Molecular Diagnos-
tics, Pleasanton, CA) beginning at the time of TLI and
ATG administration, for the first 100 days posttrans-
plantation. The detection of virus led to preemptive
treatment with intravenous ganciclovir or oral valgan-
ciclovir with a minimum of 2 weeks of induction ther-
apy according to an established on-site protocol.
Evaluation for aGVHD was performed on a routine
basis; grade II to IV disease was treated with immuno-
suppression typically beginning with a corticosteroid
at a dose of 1-2 mg/kg/day of a prednisone equivalent.Statistical Analysis
CMV PCR results and other laboratory data were
obtained by review of the electronic medical record
and combined with a preexisting database containing
patient characteristics. CMV reactivation was defined
as any positive CMV PCR result. An episode of reacti-
vation was considered resolved after 2 consecutive
CMV PCR tests were negative. Statistical analysis was
performed using SAS Enterprise Guide (version 9).
Two-tailed tests were used, with P\ .05 connoting
statistical significance. The Fisher’s exact test was
used to analyze associations between categoric vari-
ables, and continuous variables that did not display
a normal distribution were analyzed using the Mann-
Whitney U test. Correction for multiple comparisons
was not performed as few differences between groups
were detected.
Logistic regression for the occurrence of CMV re-
activation was initially performed by univariate analy-
sis. Following this, backward stepwise regression was
used to determine which variables would be included
in the multivariate model to generate adjusted odds ra-
tios. Myelodysplastic syndrome (MDS) was used as the
comparator group for disease type because that group
had the lowest incidence of CMV reactivation. All
continuous variables were first analyzed for linearity
in the logit; variables not meeting this criterion were
transformed into categoric variables using clinically
relevant cutpoints (eg, age .55 years, chimerism
.95%). Nonbinary categoric variables, such as se-
rogroup and donor type, were analyzed using dummy
coding; the group least associated with CMV reactiva-
tion was used as the reference group. All analyses
satisfied convergence criterion, and colinearity was
not observed between variables. The area under the
curve (AUC) for CMV PCR results was calculated
for each patient by multiplying the time between se-
quential positive PCR values by the PCR copy num-
ber, and summing the total of areas for each patient.
Values for each group were compared for statistical
significance using the Mann-Whitney U test.
Table 1. Baseline Characteristics of Patients Studied
R2/D+
n 5 15
R+/D+
n 5 57
R+/D2
n 5 45
Gender
Biol Blood Marrow Transplant 17:693-702, 2011 695CMV Viremia after Nonmyeloablative HCTRetrospective analysis of outcomes in patients un-
dergoing NMA HCT was reviewed with the approval
of the local institutional review board as administered
by theStanfordUniversityResearchComplianceOffice.Men 11(73.3) 26 (45.6) 24 (53.3)
Women 4 (26.7) 31 (54.4) 21 (46.7)
Underlying disease type
MDS 2 (13.3) 9 (15.8) 7 (15.6)
CLL/CML 3 (20.0) 11 (19.3) 7 (15.6)
HD/NHL 7 (46.7) 16 (28.1) 14 (31.1)
ALL/ANLL 3 (20.0) 21 (36.8) 17 (37.8)
Disease state at transplant*
Relapse 3 (21.4) 9 (15.8) 8 (18.2)
Partial remission 5 (35.7) 17 (29.8) 16 (36.4)
Complete remission 6 (42.9) 31 (54.4) 20 (45.4)
Donor type
MRD 8 (53.3) 35 (61.4) 19 (42.2)
Haplo/PMRD 1 (6.7) 5 (8.8) 2 (4.4)
URD 6 (40.0) 17 (29.8) 24 (53.3)
Age 55 (27-64) 56 (23-66) 58 (21-67)
Follow-up time (days) 437 518 504
MDS indicates myelodysplastic syndrome; CLL, chronic lymphocytic
leukemia; CML, chronic myelogenous leukemia; HD, Hodgkin’s disease;
NHL, non-Hodgkin’s lymphoma; ALL, acute lymphocytic leukemia; ANLL,
acute nonlymphocytic leukemia; MRD, matched related donor; PMRD,
partially matched related donor: URD, unrelated donor. Patients under-
going HCT following a TLI/ATG-based, nonmyeloablative preparative
regimen were analyzed for pretransplant characteristics by CMV se-
rogroup. For each variable presented the number of patients in each
group is followed by parenthesis indicating percentage for each se-
rogroup category. Age is expressed in median years followed by range,
and follow-up time is expressed as median days. No categories were
significantly different between serogroups by Fisher exact for categoric
variables and Mann-Whitney U test for continuous variables. The Fisher
exact test was used for disease type, relapse status at transplant, and
donor type.
*Two patients (one R+/D2 and 1 R2/D+) had missing information
regarding disease state at transplant.RESULTS
Pretransplantation Patient Characteristics and
Outcomes
A total of 117 patients with either donor or recip-
ient seropositivity to CMV who underwent NMA
HCT with TLI-ATG preconditioning at Stanford
University between 2001 and 2007 were analyzed.
Fifty-seven had both donor and recipient CMV sero-
positivity (R1/D1) and 60 had divergent seropositivity
status between donor and recipient, with 15 R2/D1
patients and 45 R1/D2 patients.
Patient information divided by seropositivity
group is shown in Table 1. There were no differences
between the groups with respect to demographic or
transplant-related characteristics, nor did they differ
significantly in type of underlying hematologic disease,
disease status at time of transplant, relatedness of
transplant donor, or length of follow-up. Following
transplantation, recipient/donor chimerism, incidence
of aGVHD, and incidence of death in the first 100 days
did not differ between the 3 seropositivity groups (data
not shown). The incidence of aGVHD of grade II or
greater was\10% in all serogroups. The overall inci-
dence of death in all 3 groups in the first 100 days after
transplant was 6% and occurred at a median of 64 days
after transplantation. Cause of death was primarily
because of relapse of underlying hematologic disease,
with no cases of death because of CMV disease in the
first 100 days. Kaplan-Meier analysis showed no sig-
nificant difference in survival by serogroup, even
when compared to R2/D2 patients (data not shown).Factors Associated with CMV Reactivation
Quantitative determination of CMV viral load by
PCR over time for each patient who experienced either
single or multiple episodes of reactivation, segregated
by serostatus, are shown in Figure 1. Incidence of vire-
mia during the first 100 days differed significantly in
the R2/D1 group compared with the other 2 groups
in which the recipients were seropositive. In the R2/
D1 group, 13% (2/15) of patients had detectable vire-
mia. In contrast, viremia was detected in 61% (35/57)
and 64% (29/45) of the R1/D1 group and the R1/
D2 group, respectively, which were both significantly
greater than the frequency of viremia seen in the R2/
D1 group (P 5 .001 by Fisher’s exact test; odds ratio
(OR) of 10.3 (95% confidence interval [CI] 2.1-50.2)
for the R1/D1 group and 11.8 (95% CI 2.4-58.9)
for the R1/D2 group) (Table 2). Two cases ofnonfatal CMV disease, 1 in the R1/D1 group and 1
in the R1/D2 group, both with gastrointestinal in-
volvement, occurred in the first 100 days posttransplant.
Although various transplant-related risk factors
have been associated with CMV viremia, in our analy-
sis only acute lymphoblastic leukemia (ALL) or acute
myelogenous leukemia (AML) as an underlying dis-
ease, use of an unrelated donor, and recipient seropos-
itivity were statistically associated with increased risk
for CMV viremia in univariate analysis. Multivariate
analysis was also performed and confirmed the statisti-
cally significant increased risk for seropositive patients
as well as for disease type. Age over 55 years, disease
status at transplantation, donor type, aGVHD, chime-
rism .95% at day 90, and use of steroids were not
associated with an increased risk of viremia during
the first 100 days posttransplantation (Table 2).
In the analyses presented before, a clear difference
was consistently seen between the R2/D1 group and
the 2 R1 groups, as well as a trend toward increased
CMV viremia in the R1/D2 compared with the R1/
D1 group. To quantitatively characterize the number
and duration of observed episodes ofCMVviremia, the
area under the curve (AUC) was calculated for each
Figure 1. Weekly CMV PCRmeasurements in the first 100 days posttransplant, separated by serology group and by number of reactivations. CMV PCR
results are shown (y-axis), graphed against time after transplantation in days (x-axis). Each patient is represented by a different symbol and color; the left-
hand column displays results falling within 0 to 15,000 copy number, and those with 15,000 to 150,000 copy number are displayed in the right- hand
column. (A) Patients experiencing single viremia episodes separated by serology group. (B) R1/D1 and R1/D2 patients experiencing multiple viremia
episodes. No patients in the R2/D1 experiencedmultiple episodes of viremia, and no patients in the R1/D2 group had multiple viremia episodes in the
15,000 to 150,000 range.
696 Biol Blood Marrow Transplant 17:693-702, 2011J. M. Schaenman et al.patient undergoing anyCMV reactivation by summing
the areas created by multiplying CMV PCR results
times the length of time in days betweenCMVPCR re-
sults (Figures 1 and 2). Only PCR results .600 were
used for this numeric analysis. The AUC of viremiawas greater for the 2 R1 groups when compared to
the R2/D1 group (P 5 .005). Furthermore, the R1/
D2 group had a greater AUC of viremia than the
R1/D1 group (103,000 versus 71,000, P 5 .049)
(Figure 2).
Table 2. Analysis of Factors Affecting CMV Reactivation
Univariate
P-value
Multivariate
P-valueOR (95% CI) OR (95% CI)
Serogroup
R2/D+ 1.0 (reference group) N/A 1.0 (reference group) N/A
R+/D+ 10.3 (2.1-50.3) .004* 23.8 (2.8-202.6) .004*
R+/D2 11.8 (2.4-58.9) .003* 25.7 (3.0-222.2) .003*
Age >55 1.5 (.70-3.1) .319 ND
Disease type
MDS 1.0 (reference group) N/A 1.0 (reference group) N/A
CML/CLL 1.8 (.50-6.7) .368 3.4 (.77-14.5) .106
NHL/HD 2.4 (.73-7.6) .153 4.9 (1.2-119.1) .023*
ALL/AML 5.5 (1.6-18.1) .006* 9.7 (2.5-38.3) .001*
Disease status
Remission 1.0 (reference group) N/A ND
Partial remission .93 (.40-2.1) .865 ND
Relapse .45 (.16-1.3) .133 ND
Donor type
MRD 1.0 (reference group) N/A ND N/A
Haplo/PMRD 3.4 (.64-18.2) .151 ND
URD 2.2 (1.0-4.8) .048* ND
aGVHD 4.5 (.93-21.3) .062 ND
aGVHD (>1) 4.1 (.46-36.2) .204 ND
Steroid use 2.2 (.79-6.2) .132 ND
Chimerism >95% (d90) 1.1 (.50-2.2) .892 ND
CI indicates confidence interval; OR, odds ratio; aGVHD, acute graft-versus-host disease; URD, unrelated donor; MRD, matched related donor; PMRD,
partially matched related donor; MDS myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HD, Hodg-
kin disease; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia.
In a univariate logistic regression, CMV seropositivity group (R2/D+, R+/D+, or R+/D2), underlying disease, and donor type were all associated with an
increased likelihood of CMV reactivation (P < .050). A trend toward increased reactivation was seen with steroid use and aGVHD. Multivariate analysis
demonstrated that only CMV seropositivity group and disease type were associated with increased odds of reactivation; adjustedORs are shown for the
variables included in this analysis, ND indicates multivariable analysis was not done.
*Statistically significant results compared to relevant reference group (P < .050).
Biol Blood Marrow Transplant 17:693-702, 2011 697CMV Viremia after Nonmyeloablative HCTTiming and Multiplicity of CMV Reactivations
Analysis of the number of reactivation episodes per
patient by CMV seropositivity group is shown in
Figure 3A. In the R2/D1 group, there were no epi-
sodes of multiple reactivations. In the R1/D1 group,
54% experienced single and 7% experienced multiple
episodes of reactivation. In contrast, in the R1/D2
group 44% of patients had single and 20% had multi-
ple episodes of reactivation. This difference in the
number of episodes of viremia was statistically signifi-
cant when all 3 serogroups were compared (P 5 .002
by Fisher’s exact test), but statistical significance was
not seen between the R1/D2 and R1/D1 groups
(P 5 .15 by Fisher’s exact test).
Also observed was a trend toward an earlier median
day of reactivation posttransplantation in the R1/D1
and R1/D2 groups compared with the R2/D1
group (P5 .11), with a median time of first positive
CMV PCR at 56 days posttransplant for the R2/D1
serogroup compared with 17 days for the R1/D1
patients and 11 days for the R1/D2 patients
(Figure 3A).
A strong association was seen betweenmultiple ep-
isodes of viremia and an earlier occurrence of viremia
posttransplantation: For patients experiencing a single
episode of viremia, the median number of days to first
positive PCR result was 17, whereas for patients whoeventually experienced multiple episodes of viremia,
the first detectable episode of viremia occurred at ame-
dian of 10 days after transplant (P5 .008) (Figure 3B).
Flow Cytometric Analysis of T Cell Subsets
Analysis of absolute lymphocyte counts (ALC) and
CD31, CD41, CD81, and CD191 T cell and natural
killer (NK) cell subsets by flow cytometry were per-
formed within 2 weeks of the target time points of
25, 56, and 90 days after transplant, excluding flow cy-
tometry results for patient with a diagnosis of CLL or
with relapsed or progressive disease prior to day 56 af-
ter transplant, for an average of 61% of the patients in
each seropositivity group (Figure 4). There were no
differences in CD191 counts between groups at any
time point. By day 190, patients in both R1 groups
had significantly higher ALC and subset counts than
the patients in the R2 groups (Figure 4). In the R2/
D2 group, absolute NK cells were significantly higher
than those from the R1/D2 group at days 56 and 90,
CMV viremia during the first 100 days posttransplant
was associated with a significant trend toward lower
cell ALC, CD31, CD41, and CD81 counts; for the
NK cell population this trend was observed primarily
at day 128 (Figure 5). However, this observation
was most striking in certain serogroups; for example,
we did note that the median CD41 counts were
Figure 2. Area under the curve (AUC) of CMV PCR viremia by serol-
ogy group. AUC was calculated for each patient by summing the areas
generated using the time between CMV PCR results as ‘‘length’’ and
the CMV PCR copy number as ‘‘height.’’ Patients in the R2/D1 serology
group are indicated by circles, R1/D1 by triangles, and R1/D2 by
squares. Break in y-axis scale is indicated by a double line. Mann-
Whitney U comparison between all 3 groups was statistically significant
(P5 .005) as was the comparison between the R1/D1 and R2/D1 se-
rotypes (P 5 .049). Red horizontal bars on scatterplot graph indicate
means for each serology group; asterisks (*) indicate statistically signifi-
cant comparisons.
Figure 3. Percentage of patients experiencing CMV viremia and days to
first episode by serology group. (A) Percentage of patients with either 0,
1, or .1 episodes of CMV viremia within each serology group are
indicated by white, gray, and black bars, respectively. A maximum of 2
episodes of viremia per patient were seen in the R1/D1 group, and
a maximum of 3 episodes of viremia per patient were seen in the R1/
D2 group. The number of episodes by serology typewas statistically sig-
nificantly different between all 3 groups (P 5 .002, Fisher’s exact test).
Median time in days to reactivation is indicated below the bar graph.
There was a trend toward shorter time to reactivation in the R2/D1
group (P 5 .11) compared with the other 2 serology groups. Range of
698 Biol Blood Marrow Transplant 17:693-702, 2011J. M. Schaenman et al.significantly lower in the R1/D1 patients who had an
episode of viremia when compared to their cohorts in
whomCMV viremia had not been detected (P5 .014).days to reactivation was 38 to 74 days in the R2/D1 group, 24 to 53
days in the R1/D1 group, and 211 to 46 days in the R1/D2 groups.
(B) Sixty-six patients who experienced 1 or more episodes of CMV vi-
remia were grouped by single versus multiple episode status (regardless
of serology group). Horizontal bars within the scatter plot indicate the
median number of days to first detectable CMV PCR, which was signif-
icantly different between the 2 groups (P5.008). The median day to first
episode of viremia was 17 (range: 24 to 74) in the single episode of
viremia group (n 5 53), versus 10 (range: 211 to 31) in the multiple
episode group (n 5 13). Asterisk (*) indicates statistically significant
comparisons.DISCUSSION
This analysis of CMV viremia after NMA alloge-
neic HCT using a preparative regimen of TLI and
ATG revealed several important findings that reflect
the factors that influence functional immune reconsti-
tution and control of viremia. Following TLI-ATG,
the median time to onset of CMV viremia was\18
days, in contrast to 60 days followingNMApreparative
regimens that included fludarabine and total body irra-
diation [7,8]. After MA preparative regimens, median
time to CMV viremia has frequently been reported to
be around 30 days posttransplant [9-11].
Of potentially greater significance is that the earlier
reactivation seen following this TLI-ATG preparative
regimen is correlated with a significant risk of multiple
episodes of viremia. In contrast to NMA preparativeregimens that did not include ATG [7], 18% of our
patients in the R1/D2 group experienced multiple
reactivations despite a minimum of 3 weeks of antiviral
therapy and confirmation of clearance of viremia.
Other reports of HCT following NMA prepara-
tive regimens containing ATG noted the potential
for recurrent CMV disease [12,13]. However, both
reports summarize a series of patients at a single
center who received a preparative regimen including
Figure 4. Flow cytometry results by day after transplant and serology group. Means 6 standard error of absolute cell count for each cell type are
graphed with absolute lymphocyte (ALC) in black, CD31 with dots (CD31), CD41 in lines (CD41), and CD81 in gray (CD81) at day 28, day 56,
and day 90 after transplant. The number of patients with evaluable results within each serology group are shown below. Patient results were not included
if the patient had a diagnosis of CLL as their underlying disease or if they experienced documented relapse prior to day 56 posttransplant. Means that
were statistically significantly higher than the other groups are indicated by single asterisk (*); means that were statistically significantly than the
2 R2 groups are indicated by a double asterisk (**). Statistical analysis performed using the Mann-Whitney U test. Pound sign (#) indicates a mean
that was statistically significantly higher than the R1/D2 group.
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days 24 to 21. In the more recent of the 2 analyses,
the 14.2% of 84 patients had multiple viremias
following the initial viremia that occurred at
a median of 37 days HCT. There were no analyses
regarding the effect of time of reactivation on
recurrent viremia. As may be predicted, the earlier
administration of TLI and ATG (days 211 through
27) resulted in viremia occurring earlier during the
initial period of immune reconstitution (median day
117 and day 111 for the R1/D1 and R1/D2
patients, respectively). Furthermore, the association
between early viremia and the risk of subsequentFigure 5. Mean cell count by cell type and experience of CMV viremia. Mean
each cell type at days 28, 56, and 90 posttranplantation. Means of cell counts f
shown by black squares; thosewithout CMV viremia in the first 100 days after tr
and CD191 values compared with the other cell types. Asterisks indicated stepisodes of viremia suggests that a degree of tolerance
may have resulted because of viral antigen exposure to
differentiating T cells.
The inclusion of alemtuzumab as part of an
NMA preparative regimen has been shown to result
in even higher rates of recurrence of CMV viremia
(54%-90%) despite the fact that initial viremia
occurred significantly later than in our series [14,15].
These observations are consistent with a more
profound impact on both numbers and recovery of
lymphocytes and CD41, CD81, CD191, and NK
cells as a result of alemtuzumab when compared to
ATG [16].cell counts are indicated by squares with flanking standard error bars for
rom patients who experienced 1 or more episodes of CMV viremia are
ansplant are shown by open squares. Y-axis scale is smaller for the CD41
atistically significant difference by Mann-Whitney U test.
700 Biol Blood Marrow Transplant 17:693-702, 2011J. M. Schaenman et al.To further understand the association between
CMV and immune reconstitution, we analyzed the
temporal sequence of quantitative lymphocyte recov-
ery. The critical role of CMV-specific CD41 and
CD81 T cells in functional viral control has been
well documented and low levels of total as well as
CMV-specific CD41 and CD81 cells are associated
with reactivation [3,4]. Transfer of either CD41 or
CD81CMV-specific cells has been shown to boost im-
munity and allow control of CMV infection in patients
not responding to antiviral therapy alone, and trials are
currently underway to test the impact of transferring
bothCD41 andCD81 cells simultaneously [17]. Addi-
tionally, after CMV reactivation, increases in CMV-
specific CD41 and CD81 populations have been
shown to be associated with successful control of
CMV [4,18,19]. Although our study is limited by the
absence of data regarding CMV-specific lymphocyte
responses, viremia was associated with lower ALC,
CD31, CD41, andCD81 counts at day 56, and a trend
toward lowerNKcell counts at day 28 (Figure 5).How-
ever, because our flow cytometry measurement began
at day 28 after transplant it is not possible to distinguish
whether depressed lymphocyte levels might be a con-
tributing risk factor for or a consequence of viremia
in the early posttransplant period.
It is unclear why patients in the R1/D1 group had
significantly higher ALC and lymphocyte subsets when
compared with the other groups independent of de-
tectable CMV viremia (Figure 4). As this group of pa-
tients demonstrated improved viral control following
HCT, it is reasonable to hypothesize that a synergistic
interaction between CMV-specific CD41 and CD81
cells from both donor and recipient may lead to en-
hanced lymphocyte expansion after transplantation.
Alternatively, other as of yet unidentified factors may
result in enhanced lymphocyte reconstitution in these
patients.
The association we observed between viremia dur-
ing the early period of immune reconstitution and the
appearance of multiple episodes of reactivation despite
appropriate antiviral treatment suggests an impaired im-
mune control of CMV replication, especially in theR1/
D2 setting. A similar situation may be seen in children
congenitally infected with CMV who are exposed to
the virus during a period of immune system develop-
ment and exhibit a selective defect in immune control
of CMV compared with other herpesvirues, leading to
persistent shedding of virus in saliva and urine [20].
More recent studies have suggested that this lack of ef-
fective immune control may be because of decreased in-
terferon-g response from CD4 T cells in neonates
compared with infected adults [21,22]. In prospective
analyses, we are also studying potentially important
factors influencing reconstitution of antiviral immunity
such as differences in ATG pharmacokinetics, chime-
rism at earlier timepoints, and NK-T cell populations.Patients with lower CMV-specific lymphocyte
responses as quantitated by tetramer and functional as-
says have been shown to be more likely to experience
recurrent viremia [19]. We are now prospectively ana-
lyzing the timing of CMV viremia on the kinetics of
the reconstitution of quantitative and functional
CMV-specific immunity following TLI-ATG.
The contributory role of donor seropositivity re-
mains controversial. Donor seropositivity is not always
salutary, as some observed decreased CMV viremia,
disease, and patient survival, whereas others reported
the opposite effect [1,2]. In our study, the relative
contribution of donor seropositivity depended largely
on the serostatus of the recipient. In seronegative
patients who received grafts from CMV seropositive
donors, a single episode of low grade viremia
occurred later posttransplant and resolved promptly in
association with preemptive therapy. In seropositive
patients, however, we found that donor CMV
serostatus also had an important influence on control
of CMV replication with increased efficiency of
immunologic control in the R1/D1 group as
reflected by the lower viral load AUC compared with
the R1/D2 group. This observation suggests that,
in addition to the hematopoietic progenitor cells
transferred in the graft, mature T cells with CMV-
specific activity were also present, leading to expansion
and better control of infection after exposure to CMV
antigen. The transfer of CMV-specific cells has been
demonstrated in MA allogeneic HCT [23].
Other patient factors found in our study to play an
important role in control of CMV reactivation after
NMA transplant were donor relatedness and underly-
ing hematologic disease. aGVHD also demonstrated
a trend toward increased rate of CMV viremia. There
may be a direct connection between immune dysregu-
lation caused by GVHD and lack of immune control
for CMV, or it may be possible that the presence of
GVHD was a marker for high dose steroid use, which
has been shown to contribute to CMV reactivation and
disease [3]. Increased incidence of CMV reactivation
and disease has also been shown previously to be influ-
enced by donor relatedness, with increased burden of
infection in patients receiving unrelated donor grafts
[1]. In our study, consistent with previous reports,
aGVHD is a rare event; therefore, the observations
we have made regarding antiviral immune reconstitu-
tion are of particular significance as they occurred
largely in the absence of this confounding factor. Be-
cause there were relatively few patients with haploi-
dentical or partially matched donors, the effect of
donor mismatch could not be fully assessed in this
study (Table 2).
Regarding underlying disease, however, it is un-
clear why an increase in odds of reactivation was
observed in the patient with ALL and AML, particu-
larly as there was no association between disease status
Biol Blood Marrow Transplant 17:693-702, 2011 701CMV Viremia after Nonmyeloablative HCTat transplant and viremia, although this may have been
a chance observation. If a true association, it may re-
flect the contribution of recipient immunity to control
of CMV replication in the early posttransplant period
in the NMA situation where the patient’s native im-
mune system persists for some time as reflected by
the measurements of chimerism showing persistent re-
cipient cells at day 90 after transplant. It is possible that
residual T cells in leukemic patients are less able to con-
tribute to functional control of virus during the early
period of immune reconstitution. Alternatively, the
lymphocyte-targeting therapies for ALL that patients
receive prior to transplantation may influence viral
control; however, we lack sufficient numbers
of patients to determine the impact of this potential
factor.
In addition to the limitations of this study as a ret-
rospective analysis, the standard practice of adminis-
tering preemptive antiviral treatment at the first
evidence of viremia precludes a study of the natural
history of CMV reactivation and immune control.
The AUC calculation, although useful in studies of
CMV replication [24], is somewhat difficult to inter-
pret in the setting of antiviral administration, although
the patients in this cohort were all treated for CMV
according to a standardized protocol.
In addition, because the seropositive patients uni-
formly experienced early CMV viremia, it is difficult
to separate the contribution of early viral exposure
and recipient CMV serostatus in control of viral repli-
cation. Further studies in a mouse model of allogeneic
transplant will allow the dissection of factors that con-
tribute to an effective and durable immune response in
the setting of NMA preparative regimens. Further-
more, these experiments would permit analysis of the
relative contributions of host-versus-donor-derived
cells in antiviral responses.
As transplant protocols continue to evolve, so will
the understanding of the complex modulation of im-
mune reconstitution. Our findings uniquely demon-
strate the dynamic nature of immunity in relation to
CMV antigen exposure in the complex environment
resulting from NMA conditions where both residual
recipient as well as donor immune response may
contribute to viral control. Continued study of this
common posttransplant viral infection will provide in-
sight into the recapitulation of a functional immune
system after allogeneic HCT in the setting of recipient
immunomodulation.ACKNOWLEDGMENTS
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